MEPRO-ASPIRIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mepro-aspirin, and what generic alternatives are available?
Mepro-aspirin is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in MEPRO-ASPIRIN is aspirin; meprobamate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; meprobamate profile page.
Summary for MEPRO-ASPIRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 1,575 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MEPRO-ASPIRIN at DailyMed |
Recent Clinical Trials for MEPRO-ASPIRIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Erasmus Medical Center | Phase 2 |
| Academisch Ziekenhuis Groningen | Phase 2 |
| Leiden University Medical Center | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for MEPRO-ASPIRIN
US Patents and Regulatory Information for MEPRO-ASPIRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | MEPRO-ASPIRIN | aspirin; meprobamate | TABLET;ORAL | 089127-001 | Mar 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
